Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 10, 2005, Pages 963-969

  Penning, C ^a   Vecht, J ^b   Masclee, A A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOOD INTAKE; HUMAN; MALE; POSTGASTRECTOMY SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

BODY WEIGHT; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DUMPING SYNDROME; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 27744438296     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02681.x     Document Type: Article

References (21)

1. Vecht J, Masclee AA, Lamers CB. The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol Suppl 1997; 223: 21-7.
2. Lyons TJ, McLoughlin JC, Shaw C, Buchanan KD. Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome. Digestion 1985; 31: 89-96.
3. Hopman WP, Wolberink RG, Lamers CB, Van Tongeren JH. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Ann Surg 1988; 207: 155-9.
4. Tulassay Z, Tulassay T, Gupta R, Cierny G. Long acting somatostatin analogue in dumping syndrome. Br J Surg 1989; 76: 1294-5.
5. Geer RJ, Richards WO, O'Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990; 212: 678-87.
6. Richards WO, Geer R, O'Dorisio TM, et al. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 1990; 49: 483-7.
7. Kooner JS, Peart WS, Mathias CJ. The peptide release inhibitor, octreotide (SMS 201-995), prevents the haemodynamic changes following food ingestion in normal human subjects. Q J Exp Physiol 1989; 74: 569-72.
8. Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996; 277: 1359-65.
9. Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg 1991; 126: 1231-5; discussion 35-6.
10. Vecht J, Lamers CB, Masclee AA. Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol (Oxf) 1999; 51: 619-24.
11. Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 1996; 45: 67-71.
12. Mangupli R, Lisette A, Ivett C, Paul C, de los Rios Victoria C, Luis CJ. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003; 6: 29-34.
13. Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001; 96: 1494-8.
14. Arnold R, Frank M. Gastrointestinal endocrine tumours: medical management. Baillieres Clin Gastroenterol 1996; 10: 737-59.
15. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-44.
16. van der Kleij FG, Vecht J, Lamers CB, Masclee AA. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol 1996; 31: 1162-6.
17. Eypasch E, Williams JI, Wood-Dauphinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216-22.
18. van de Kamer JH, Huinink HTB, Weyers HA. Rapid method for determination of fat in feces. J Biol Chem 1949; 177: 349-55.
19. Kamoi K, Miyakoshi M, Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004; 64: 19-25.
20. Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab 2003; 88: 2037-44.
21. Norrelund H, Hansen TK, Orskov H, et al. Ghrelin immunoreactivity in human plasma is suppressed by somatostatin. Clin Endocrinol (Oxf) 2002; 57: 539-46.